Molecular and Cellular Biology in Renal and Vascular Pathology. IIS-Fundación Jiménez Díaz, Universidad Autónoma Madrid, Madrid, Spain.
Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Hospital Universitario Reina Sofía, Cordoba, Spain.
J Pathol. 2023 Oct;261(2):169-183. doi: 10.1002/path.6161. Epub 2023 Aug 9.
Intravascular hemolysis is a common feature of different clinical entities, including sickle cell disease and malaria. Chronic hemolytic disorders are associated with hepatic damage; however, it is unknown whether heme disturbs lipid metabolism and promotes liver steatosis, thereby favoring the progression to nonalcoholic fatty liver disease (NAFLD). Using an experimental model of acute intravascular hemolysis, we report here the presence of liver injury in association with microvesicular lipid droplet deposition. Hemolysis promoted serum hyperlipidemia and altered intrahepatic triglyceride fatty acid composition, with increments in oleic, palmitoleic, and palmitic acids. These findings were related to augmented expression of transporters involved in fatty acid uptake (CD36 and MSR1) and deregulation of LDL transport, as demonstrated by decreased levels of LDL receptor and increased PCSK9 expression. Hemolysis also upregulated hepatic enzymes associated with cholesterol biosynthesis (SREBP2, HMGC1, LCAT, SOAT1) and transcription factors regulating lipid metabolism (SREBP1). Increased LC3II/LC3I ratio and p62/SQSTM1 protein levels were reported in mice with intravascular hemolysis and hepatocytes stimulated with heme, indicating a blockade of lipophagy. In cultured hepatocytes, cell pretreatment with the autophagy inductor rapamycin diminished heme-mediated toxicity and accumulation of lipid droplets. In conclusion, intravascular hemolysis enhances liver damage by exacerbating lipid accumulation and blocking the lipophagy pathway, thereby promoting NAFLD. These new findings have a high translational potential as a novel NAFLD-promoting mechanism in individuals suffering from severe hemolysis episodes. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
血管内溶血是多种临床实体的共同特征,包括镰状细胞病和疟疾。慢性溶血性疾病与肝损伤有关;然而,尚不清楚血红素是否会干扰脂质代谢并促进肝脂肪变性,从而有利于向非酒精性脂肪性肝病 (NAFLD) 进展。在这里,我们使用急性血管内溶血的实验模型报告了与微小脂滴沉积相关的肝损伤的存在。溶血促进血清高脂血症并改变肝内甘油三酯脂肪酸组成,增加油酸、棕榈油酸和棕榈酸。这些发现与参与脂肪酸摄取的转运蛋白(CD36 和 MSR1)的表达增加和 LDL 转运的失调有关,表现为 LDL 受体水平降低和 PCSK9 表达增加。溶血还上调了与胆固醇生物合成相关的肝酶(SREBP2、HMGC1、LCAT、SOAT1)和调节脂质代谢的转录因子(SREBP1)。在血管内溶血的小鼠和用血红素刺激的肝细胞中,报告了 LC3II/LC3I 比率和 p62/SQSTM1 蛋白水平增加,表明脂噬作用受阻。在培养的肝细胞中,细胞用自噬诱导剂雷帕霉素预处理可减少血红素介导的毒性和脂滴积累。总之,血管内溶血通过加剧脂质积累和阻断脂噬途径来加重肝损伤,从而促进 NAFLD。这些新发现具有很高的转化潜力,可作为严重溶血发作个体中促进 NAFLD 的新机制。